Insight on Oncology in Europe

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | » »|

Type Product title / description Pub Price
Report
Report

Treatment Algorithms: Rectal Cancer – Inclusion of chemoradiation can influence treatment and prescribing trends

This report provides analysis of current treatment dynamics of rectal cancer. Based on Datamonitor’s survey of 127 oncologists and cancer treaters the report assesses treatment type, prescribing influences, and patient numbers across disease stages.

Published By Datamonitor
26 Apr 2012 $4800
Buy
Report
Report

Treatment Algorithms: Prostate Cancer

Analysis of current treatment dynamics of prostate cancer. The report assesses uptake rates and order or treatment types across the seven major markets using Datamonitor’s primary physician research of 124 medical oncologists and urologists.

Published By Datamonitor
21 Dec 2011 $4800
Buy
Report
Report

Treatment Algorithms: Non-Small Cell Lung Cancer – Molecular profiling will increasingly guide the choice of therapy

This report provides analysis of current treatment dynamics of non-small cell lung cancer. Based on Datamonitor’s survey of 129 oncologists, the report assesses treatment type, prescribing influences, and patient numbers across disease stages.

Published By Datamonitor
09 Oct 2012 $4800
Buy
Report
Report

Treatment Algorithms: Melanoma – High cost of novel therapies limits uptake

This report provides analysis of current treatment dynamics of melanoma. Based on Datamonitor’s survey of 107 oncologists, the report assesses treatment type, prescribing influences, and patient numbers across disease stages.

Published By Datamonitor
29 Aug 2012 $4800
Buy
Report
Report

Treatment Algorithms: Colon Cancer – Treatment dictated by stage, prior therapy, and reimbursement

This report provides analysis of current treatment dynamics of colon cancer. Based on Datamonitor’s survey of 126 oncologists and cancer treaters the report assesses treatment type, prescribing influences, and patient numbers across disease stages.

Published By Datamonitor
26 Apr 2012 $4800
Buy
Report
Report

Treatment Algorithms: Breast Cancer (HER2-Negative/Hormone Receptor-Positive) – Diverse drug combinations employed to overcome resistance

Analysis of current treatment dynamics of HER2-negative/hormone receptor-positive breast cancer. The report assesses uptake rates and treatment types in the seven major markets using Datamonitor’s primary physician research of 130 specialists.

Published By Datamonitor
21 Mar 2012 $4800
Buy
Report
Report

The Prostate Cancer Market Outlook to 2021

Recent approvals reinvigorate mCRPC market

Published By Datamonitor
18 Jan 2013 $2800
Buy
Report
Report

The Orphan Drug Market Outlook to 2017

This report provides an analysis of the orphan drug market. It comprises brands that have gained US FDA orphan drug approval, as well as Phase III pipeline candidates that have gained an orphan drug designation from the FDA.

Published By Datamonitor
08 Jan 2013 $2800
Buy
Report
Report

Stakeholder Opinions: Hepatocellular cancer

Stakeholder Opinions: Hepatocellular Cancer discusses issues in the treatment of hepatocellular cancer, highlighting potential target populations for drug developers, treatment limitations and unmet needs, and an overview of the current pipeline.

Published By Datamonitor
01 Dec 2010 $2800
Buy
Report
Report

Stakeholder Insight: Gastric Cancer

Explores key issues in the gastric cancer market, including diagnosis and treatment patterns, specific drug regimens used at each line of therapy, key prescribing influences and predicted performance of late-phase pipeline products.

Published By Datamonitor
15 Sep 2010 $15200
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | » »|

No help is available.